Metraipolis › archive › dc_7eff2c435d48

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials — Europe PMC PMID:42540023

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42540023
DOI: 10.1093/skinhd/vzag075
License (as archived): solo-consultazione
Archived: 2026-10-06T11:27:32.839Z
SHA-256 of the archived text: 593262541459a1c2a91b939f890b82ec1cb2481cabd8c5a1237e4a29b2dafc12
Stable URL of this page: https://metraipolis.com/documento/dc_7eff2c435d48

How to cite

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials — Europe PMC PMID:42540023 — Europe PMC (en), https://europepmc.org/article/MED/42540023 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7eff2c435d48 (Metraipolis archive dc_7eff2c435d48, sha256 593262541459a1c2a91b939f890b82ec1cb2481cabd8c5a1237e4a29b2dafc12)

BibTeX

@misc{dc7eff2c435d48,
  title = {Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials — Europe PMC PMID:42540023},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42540023},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7eff2c435d48; sha256 593262541459a1c2a91b939f890b82ec1cb2481cabd8c5a1237e4a29b2dafc12},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42540023. Agents can read the archived copy with the MCP tool read_document.